US Broker Ratings

Organon & Co. (OGN) Stock Report: Unpacking a 37% Potential Upside in the Healthcare Sector

Organon & Co. (NYSE: OGN), a well-established player in the healthcare sector, has been navigating through a challenging landscape with a current stock price of $10.19. The company, with a..

Catalyst Pharmaceuticals (CPRX) Stock Analysis: A Biotech with 44.85% Upside Potential

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a rapidly growing player in the biotechnology sector, has garnered significant attention from investors due to its promising financial outlook and robust performance metrics. The..

Xenon Pharmaceuticals (XENE) Stock Analysis: Analyst Ratings Signal a 72% Upside Potential

Xenon Pharmaceuticals Inc. (NASDAQ: XENE), a pioneering force in the biotechnology sector, primarily focuses on developing innovative treatments for neurological and psychiatric disorders. Headquartered in Burnaby, Canada, Xenon has garnered..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Growth Potential in Eye Care and Beyond

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a burgeoning player in the biotechnology sector, is capturing investor attention with its focused approach to eye care therapeutics and a promising pipeline of innovative..

Schrodinger, Inc. (SDGR) Stock Analysis: Unveiling a 49.9% Potential Upside in the Health Information Services Sector

Schrodinger, Inc. (NASDAQ: SDGR), a prominent player in the health information services industry, has been capturing investor attention with its innovative approach to molecular discovery. Based in New York, the..

MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring an 82.54% Upside Potential

Investors with a keen interest in the biotechnology sector should take a closer look at MoonLake Immunotherapeutics (MLTX), a company making waves in the healthcare industry with its innovative approach..

Beam Therapeutics Inc. (BEAM) Stock Report: Evaluating a 165% Potential Upside in Biotech

Beam Therapeutics Inc. (NASDAQ: BEAM) represents a compelling opportunity within the biotechnology sector, offering investors significant upside potential, highlighted by the current analyst consensus target price suggesting a 165.14% increase..

National HealthCare Corporation (NHC) Stock Analysis: Strong Revenue Growth and Stable Dividends Make This Healthcare Company a Compelling Choice

National HealthCare Corporation (NHC), a stalwart in the healthcare sector, continues to make waves with its robust revenue growth and appealing dividend yield. With a market capitalization of $1.58 billion,..

Haemonetics Corporation (HAE) Stock Analysis: Exploring a 30% Potential Upside

Haemonetics Corporation (NYSE: HAE), a stalwart in the healthcare sector, is attracting significant attention from investors with its robust market position in the medical devices industry. With a market capitalization..

CG Oncology, Inc. (CGON)

⚠️ No article content returned.

..

Arrowhead Pharmaceuticals (ARWR) Stock Analysis: Exploring a Promising 180% Upside Potential

For individual investors seeking opportunities within the biotechnology sector, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) presents an intriguing proposition. With a market capitalization of $2.17 billion, Arrowhead is a notable player..

NovoCure Limited (NVCR): Investor Outlook Reveals an 81.91% Potential Upside

In the realm of medical devices, NovoCure Limited (NASDAQ: NVCR) stands out as a significant player, not just for its innovative approach to cancer treatment but also for the promising..

Belite Bio, Inc (BLTE) Stock Analysis: Uncovering a 41.69% Potential Upside in the Biotech Arena

Belite Bio, Inc (NASDAQ: BLTE) is capturing attention in the biotechnology sector, driven by its innovative approach to addressing significant unmet medical needs. With a market capitalization of $1.95 billion,..

ImmunityBio, Inc. (IBRX) Stock Analysis: Unveiling a 264% Potential Upside for Biotech Investors

ImmunityBio, Inc. (IBRX) stands at the forefront of cutting-edge biotechnology innovation, as it continues to make significant strides in developing therapies that enhance the immune system’s natural ability to fight..

Premier, Inc. (PINC) Stock Analysis: Navigating Healthcare Challenges with a 3.77% Dividend Yield

Premier, Inc. (NASDAQ: PINC) stands as a significant player in the healthcare sector, specifically within the Health Information Services industry. Headquartered in Charlotte, North Carolina, Premier’s dual-segment business model is..

Disc Medicine, Inc. (IRON) Stock Analysis: Exploring an 88.91% Potential Upside in the Biotech Sector

Disc Medicine, Inc. (NASDAQ: IRON) is creating a buzz in the biotechnology sector with its promising pipeline and significant upside potential for investors. With a current market capitalization of $1.8..

QuidelOrtho Corporation (QDEL) Stock Analysis: Exploring a 61.34% Potential Upside in the Healthcare Sector

QuidelOrtho Corporation (NASDAQ: QDEL) stands as a noteworthy player in the healthcare sector, specializing in medical devices and diagnostic testing solutions. With a market capitalization of $1.98 billion, the company..

Galapagos NV (GLPG) Stock Analysis: Navigating a Path with Limited Upside

For investors keen on exploring opportunities in the biotechnology sector, Galapagos NV (GLPG), headquartered in Mechelen, Belgium, presents a unique case. Specializing in developing innovative medicines targeting oncology and immunology,..

Apogee Therapeutics, Inc. (APGE) Stock Analysis: Is a 120% Upside Within Reach for This Biotech Pioneer?

Apogee Therapeutics, Inc. (APGE), a biotechnology firm rooted in the healthcare sector, is making waves with its promising portfolio of innovative treatments for various inflammatory and immunological conditions. With a..

Envista Holdings Corporation (NVST) Stock Analysis: Navigating a Challenging Landscape with Strategic Potential

Envista Holdings Corporation (NYSE: NVST) remains a company to watch in the healthcare sector, specifically within the realm of medical instruments and supplies. With a market capitalization of $3.22 billion,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds